Magnesium pyridoxal 5-phosphate glutamate
Chemical compound
- C10AX07 (WHO)
- (2S)-2,5-diamino-5-oxopentanoic acid;
(4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate
- 62055-05-4 (magnesium salt)
- 173846
- 151728
Y
- DTXSID00977622
- Interactive image
- O=C(N)CC[C@H](N)C(=O)O.O=P(O)(O)OCc1cnc(c(O)c1C=O)C
InChI
- InChI=1S/C8H10NO6P.C5H10N2O3/c1-5-8(11)7(3-10)6(2-9-5)4-15-16(12,13)14;6-3(5(9)10)1-2-4(7)8/h2-3,11H,4H2,1H3,(H2,12,13,14);3H,1-2,6H2,(H2,7,8)(H,9,10)/t;3-/m.0/s1Y
- Key:BCARVEADLDZBJT-HVDRVSQOSA-NY
Magnesium pyridoxal 5-phosphate glutamate (trade name Sedalipid) is a hypolipidemic agent.[1]
References
- ^ Schuitemaker GE, van der Pol GA, Aretz CP, Dinant GJ (2001). "A placebo-controlled, double-blind, randomised trial of magnesium-pyridoxal-5'-phosphate-glutamate for hypercholesterolaemia and other clinical-chemical risk factors of cardiovascular disease in a primary care setting". Eur. J. Clin. Pharmacol. 56 (12): 857–63. doi:10.1007/s002280000247. PMID 11317472.
- v
- t
- e
Lipid-lowering agents (C10)
| Cholesterol absorption inhibitors, NPC1L1 |
|
|---|---|
| Bile acid sequestrants/resins (LDL) |
| Statins (HMG-CoA reductase, LDL) | |
|---|---|
| Niacin and derivatives (HDL and LDL) | |
| MTTP inhibitors (VLDL) | |
| ATP citrate lyase inhibitors (LDL) | |
| Thyromimetics (VLDL) |
| PPAR agonists (LDL) |
| ||||
|---|---|---|---|---|---|
| CETP inhibitors (HDL) | |||||
| PCSK9 inhibitors (LDL) | |||||
| ANGPTL3 inhibitors (LDL/HDL) |
- Alipogene tiparvovec
- Azacosterol
- Azalanstat
- Benfluorex‡
- Darapladib§
- Lapaquistat§
- Magnesium pyridoxal 5-phosphate glutamate
- Meglutol
- Mipomersen
- Omega-3-triglycerides
- Policosanol
- Probucol
- Tiadenol
- Triparanol‡
- Volanesorsen
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
